|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer:efficacy,safety,and biomarker results from Chinese patients显示文摘Overexpression of human epidermal growth factor receptor-2(HER2) in metastatic breast cancer(MBC) is associated with poor prognosis.This single-arm open-label trial(EGF109491;NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily pretreated Chinese patients with HER2-positive MBC.The primary endpoint was clinical benefit rate(CBR).Secondary endpoints included progression-free survival(PFS),time to response(TTR),duration of response(DoR),central nervous system(CNS) as first site of relapse,and safety.The results showed that there were 23 patients with partial responses and 7 patients with stable disease,resulting in a CBR of 57.7%.The median PFS was 6.34 months(95% confidence interval,4.93-9.82 months).The median TTR and DoR were 4.07 months(range,0.03-14.78 months) and 6.93 months(range,1.45-9.72 months),respectively.Thirteen(25.0%) patients had new lesions as disease progression.Among them,2(3.8%) patients had CNS disease reported as the first relapse.The most common toxicities were palmar-plantar erythrodysesthesia(59.6%),diarrhea(48.1%),rash(48.1%),hyperbilirubinemia(34.6%),and fatigue(30.8%).Exploratory analyses of oncogenic mutations of PIK3CA suggested that of 38 patients providing a tumor sample,baseline PIK3CA mutation status was not associated with CBR(P = 0.639) or PFS(P = 0.989).These data confirm that the lapatinib plus capecitabine combination is an effective and well-tolerated treatment option for Chinese women with heavily pretreated MBC,irrespective of PIK3CA status. | Bing-He Xu Ze-Fei Jiang Daniel Chua Zhi-Min Shao Rong-Cheng Luo Xiao-Jia Wang Dong-Geng Liu Winnie Yeo Shi-Ying Yu Beth Newstat Alka Preston Anne-Marie Martin Hai-Dong Chi Li wang | 2011 | Chinese Journal of Cancer2011，30，5： | 17 |
| 2 | Value of quality of life analysis in liver cancer: A clinician's perspective显示文摘Health related quality of life(HRQOL) is increasingly recognized as an important clinical parameter and research endpoint in patients with hepatocellular carcinoma(HCC). HRQOL in HCC patients is multifaceted and affected by medical factor which encompasses HCC and its complications, oncological and palliative treatment for HCC, underlying liver disease, as well as the psychological, social or spiritual reaction to the disease. Many patients presented late with advanced disease and limited survival, plagued with multiple symptoms, rendering QOL a very important aspect in their general well being. Various instruments have been developed and validated to measure and report HRQOL in HCC patients, these included general HRQOL instruments, e.g., Short form(SF)-36, SF-12, Euro Qo L-5D, World Health Organization Quality of Life Assessment 100(WHOQOL-100), World Health Organization Quality of Life Assessment abbreviated version; general cancer HRQOL instruments, e.g., the European Organisation for Research and Treatment of Cancer(EORTC) QLQ-C30, Functional Assessment of Cancer Therapy(FACT)-General, Spitzer Quality of Life Index; and liver-cancer specific HRQOL instruments, e.g., EORTC QLQ-HCC18, FACT-Hepatobiliary(FACT-Hep), FACT-Hep Symptom Index, Trial Outcome Index. Important utilization of HRQOL in HCC patients included description of symptomatology and HRQOL of patients, treatment endpoint in clinical trial, prognostication of survival, benchmarking of palliative care service and health care valuation. In this review, difficulties regarding the use of HRQOL data in research and clinical practice, including choosing a suitable instrument, problems of missing data, data interpretation, analysis and presentation are examined. Potential solutions are also discussed. | Leung Li Winnie Yeo | 2017 | World Journal of Hepatology2017，9，20： | 10 |
| 3 | Risk factors and natural history of breast cancer in younger Chinese women显示文摘AIM: To investigate the age differences in the risk factors, clinicopathological characteristics and patterns of treatment of female breast cancer patients. METHODS: Seven thousand one hundred and fiftytwo women with primary breast cancer from the Hong Kong Breast Cancer Registry were recruited after receiving patients' consent, they were asked to complete standardized questionnaires which captured their sociodemographic characteristics and risk factors associated with breast cancer development. Among them, clinicopathological data and patterns of treatment were further collected from medical records of 5523 patients with invasive breast cancers. Patients were divided into two groups according to the age at diagnosis: younger(< 40 years old) vs older patients(≥ 40 years old) for subsequent analyses.RESULTS: Analysis on the sociodemographic characteristics and exposure to risk factors were performed on 7152 women with primary breast cancer and the results revealed that younger patients were more likely to have unhealthy lifestyles; these include a lack of exercise(85.4% vs 73.2%, P < 0.001), having high stress in life(46.1% vs 35.5%, P < 0.001), having dairy/meat-rich diets(20.2% vs 12.9%, P < 0.001),having alcohol drinking habit(7.7% vs 5.2%, P = 0.002). Younger patients were also more likely to have hormone-related risk factors including nulliparity(43.3% vs 17.8%, P < 0.001) and an early age at menarche(20.7% vs 13.2%, P < 0.001). Analyses on clinicopathological characteristics and patterns of treatment were performed on 5523 women diagnosed with invasive breast cancer. The invasive tumours in younger patients showed more aggressive pathological features such as having a higher percentage of grade 3 histology(45.7% vs 36.5%, P < 0.001), having a higher proportion of tumours with lymphovascular invasion(39.6% vs 33.2%, P = 0.003), and having multifocal disease(15.7% vs 10.3%, P < 0.001); they received different patterns of treatment than their older counterparts.CONCLUSION: Younger patients in Hong Kong are more likely to encounter risk factors associated with breast cancer development and have more aggressive tumours than their older counterparts. | Winnie Yeo Hang-Mei Lee Amy Chan Emily YY Chan Miranda CM Chan Keeng-Wai Chan Sharon WW Chan Foon-Yiu Cheung Polly SY Cheung Peter HK Choi Josette SY Chor William WL Foo Wing-Hong Kwan Stephen CK Law Lawrence PK Li Janice WH Tsang Yuk Tung Lorna LS Wong Ting-Ting Wong Chun-Chung Yau Tsz-Kok Yau Benny CY Zee | 2014 | World Journal of Clinical Oncology2014，5，5： | 4 |
| 4 | International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study显示文摘The outcome of hepatocellular carcinoma(HCC) patients significantly differs between western and eastern population centers. Our group previously developed and validated the Chinese University Prognostic Index(CUPI) for the prognostication of HCC among the Asian HCC patient population. In the current study, we aimed to validate the CUPI using an international cohort of patients with HCC and to compare the CUPI to two widely used staging systems, the Barcelona Clinic Liver Cancer(BCLC) classification and the Cancer of the Liver Italian Program(CLIP). To accomplish this goal, two cohorts of patients were enrolled in the United Kingdom(UK; n = 567; 2006-2011) and Hong Kong(HK; n = 517; 2007-2012). The baseline clinical data were recorded. The performances of the CUPI, BCLC, and CLIP were compared in terms of a concordance index(C-index) and were evaluated in subgroups of patients according to treatment intent. The results revealed that the median follow-up durations of the UK and HK cohorts were 27.9 and 29.8 months, respectively. The median overall survival of the UK and HK cohorts were 22.9 and 8.6 months, respectively. The CUPI stratified the patients in both cohorts into three risk subgroups corresponding to distinct outcomes. The median overall survival of the CUPI low-, intermediate-, and high-risk subgroups were 3.15, 1.24, and 0.29 years, respectively, in the UK cohort and were 2.07, 0.32, and 0.10 years, respectively, in the HK cohort. For the patients who underwent curative treatment, the prognostic performance did not differ between the three staging systems, and all were suboptimal. For those who underwent palliative treatment, the CUPI displayed the highest C-index, indicating that this staging system was the most informative for both cohorts. In conclusion, the CUPI is applicable to both western and eastern HCC patient populations. The performances of the three staging systems differed according to treatment intent, and the CUPI was demonstrated to be optimal for those undergoing palliative treatment. A more precise staging system for early-stage disease patients is required. | Stephen L.Chan Philip J.Johnson Frankie Mo Sarah Berhane Mabel Teng Anthony W.H.Chan Ming C.Poon Paul B.S.Lai Simon Yu Anthony T.C.Chan Winnie Yeo | 2014 | Chinese Journal of Cancer2014，33，10： | 4 |
| 5 | Development of systemic therapy for hepatocellular carcinoma at 2013:Updates and insights显示文摘A growing number of multi-targeted tyrosine kinase inhibitor(TKI)has undergone testing for hepatocellular carcinoma(HCC).Unfortunately,this enthusiasm has recently been discouraged by a number of negative phaseⅢstudies on several anti-angiogenic TKIs in HCC.Several postulations have been made to account for this phenomenon,namely the plateau effects of anti-angiogenesis approach,the heterogeneity of HCC in terms of background hepatitis/cirrhosis and tumor biology,as well as the way how clinical trials are designed.Regardless of the underlying reasons,these results suggested that alternative strategies are necessary to further develop systemic therapy for HCC.Several new strategies are currently evaluated:for examples,molecular agents with activities against targets other than vascular endothelial growth factor receptor are being evaluated in on-going clinical trials.In addition,different approaches of targeted agents in combination with various treatment modalities,such as concurrently with another molecular agent,cytotoxic chemotherapy or transarterial chemoembolization,are being developed.This review aims to give a summary on the results of recently released clinical trials on TKIs,followed by discussion on some of the potential novel agents and combinational approaches.Future directions for testing innovative systemic agents for HCC will also be discussed. | Stephen L Chan Winnie Yeo | 2014 | World Journal of Gastroenterology2014，20，12： | 2 |
| 6 | A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma显示文摘 | Stephen L. Chan Frankie K. F. Mo Cesar S. C. Wong Charles M. L. Chan Linda K. S. Leung Edwin P. Hui Brigette B. Ma Anthony T. C. Chan Tony S. K. Mok Winnie Yeo | 2011 | Cancer2011，，16： | 2 |
| 7 | Hepatitis B virus reactiva- tion in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab 显示文摘 | Winnie Yeo Tung C Nancy WY | 2009 | Journal Of Clinical Oncology2009，27，4： | 1 |
| 8 | Lamivudine for the prevention of hepatitis B vim reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy 显示文摘 | Winnie Yeo Paul KS Wing M | 2004 | Journal Of Clinical Oneology2004，22，5： | 1 |
| 9 | A prospective study of upper gas trointestinal hemorrhage in patients with hepatocellular carcinoma显示文摘 | Winnie Yeo Mrcp JY Sung | 1995 | Dig Dis Sci1995，40，： | 1 |
| 10 | Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients显示文摘 | Winnie Yeo Wing M. Ho Pun Hui Paul K. S. Chan Kwok C. Lam Jam J. Lee Philip J. Johnson | 2004 | Breast Cancer Research and Treatment2004，，3： | 1 |
| 11 | A randomized study of aprepitant, ondansetronand dexamethasone for chemotherapy-induced nausea and vomit-ing in Chinese breast cancer patients receiving moderately eme-togenic chemotherapy Zee 显示文摘 | WINNIE YEO F | 2009 | Breast Cancer Res Treatm2009，113，4： | 1 |
| 12 | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma显示文摘 | Qian Zhou Vivian WY Lui Winnie Yeo | 2011 | Future Oncol2011，，10： | 1 |
| 13 | A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma显示文摘 | Winnie Yeo MRCP J. Y. Sung MRCP PhD S. C. Ward MRCP FRCR S. C. S. Chung MD FRCS MRCP W. Y. Lee BSc A. K. C. Li MD FRCS Professor P. J. Johnson MD FRCP | 1995 | Digestive Diseases and Sciences1995，，12： | 1 |
| 14 | Lamivudine for the prevention of hepatitis B vires reactivation in hepatitis B s-anti- gen seropositive cancer patients undergoing cytotoxic chemotherapy 显示文摘 | Winnie Yeo Paul KS Chan Wing M Ho | 2004 | Journal of Clinical Oncology2004，22，5： | 1 |
| 15 | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab 显示文摘 | Winnie Yeo Tung C Chan Nancy W Y Leung | 2009 | Journal of Clinical Oncology2009，27，4： | 1 |
| 16 | Hepatitis B virus reactivation associated with anti‐neoplastic therapy显示文摘 | Winnie Yeo Henry LY Chan | 2012 | J Gastroenterol Hepatol2012，，1： | 1 |
| 17 | A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma显示文摘 | Winnie Yeo MRCP J. Y. Sung MRCP PhD S. C. Ward MRCP FRCR S. C. S. Chung MD FRCS MRCP W. Y. Lee BSc A. K. C. Li MD FRCS Professor P. J. Johnson MD FRCP | 1995 | Digestive Diseases and Sciences1995，，12： | 1 |
| 18 | Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how?显示文摘 | Stephen L. Chan Winnie Yeo | 2013 | Asia‐Pac J Clin Oncol2013，，1： | 1 |
| 19 | Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients显示文摘 | Winnie Yeo Chan | 2011 | Breast Cancer: Targets and Therapy (default)2011，，： | 1 |
| 20 | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab显示文摘 | Winnie Yeo Tung C Chan Nancy W Y Leung | 2009 | Journal of Clinical Oncology2009，27，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员